A Phase 3 interventional study of MCI-186 and Placebo in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2011, is one of 8 in phase 3, and was the 5th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:
National Center of Neurology and Psychiatry, Japan · Sites in Japan
Ages 20+
Regeneron Pharmaceuticals · Sites in Japan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 10
First in 2007; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 136 across the 20 interventional studies, 24 across the 1 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 6 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyotrophic Lateral Sclerosis with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MCI-186 · Drug: MCI-186 in open label phase
Drug: Placebo · Drug: MCI-186 in open label phase
Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
0=worst; 48=best
Time frame: baseline and 24 weeks
Number of Participants With Death or a Specified State of Disease Progression
Any of "death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech" was defined as an event.
Time frame: 24 weeks
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
Time frame: baseline and 24 weeks
Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks
The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best
Time frame: baseline and 24 weeks
Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best
Time frame: baseline and 24 weeks
Percentage of Participants With Adverse Events
Time frame: 24 weeks
Percentage of Participants With Adverse Drug Reactions
Time frame: 24 weeks
Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of "Investigations" (PT, MedDRA Ver. 17.0)
Time frame: 24 weeks
Percentage of Participants With Abnormal Values in Sensory Examinations
Time frame: baseline and 24 weeks
| Milestone | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Started | 69 | 68 |
| Completed | 67 | 60 |
| Not completed | 2 | 8 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Due to a discontinuation criterion | 2 | 3 |
| Milestone | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Started | 65 | 58 |
| Completed | 53 | 40 |
| Not completed | 12 | 18 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Due to a discontinuation criterion | 4 | 9 |
0=worst; 48=best
| units on a scale | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks | -5.01 ± 0.64 | -7.5 ± 0.66 |
Any of "death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech" was defined as an event.
| Count of Participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Death | 0 | 0 |
| Disability of independent ambulation | 0 | 2 |
| Loss of upper limbs function | 0 | 0 |
| Tracheotomy | 1 | 0 |
| Use of respirator | 0 | 0 |
| Use of tube feeding | 0 | 1 |
| Loss of useful speech | 1 | 3 |
| percentage of FVC | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks | -15.61 ± 2.41 | -20.4 ± 2.48 |
The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best
| units on a scale | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks | -15.91 ± 1.97 | -20.8 ± 2.06 |
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best
| units on a scale | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks | 17.25 ± 3.39 | 26.04 ± 3.53 |
| percentage of Participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Percentage of Participants With Adverse Events | 84.1 | 83.8 |
| percentage of Participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Percentage of Participants With Adverse Drug Reactions | 2.9 | 7.4 |
| percentage of Participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Blood bilirubin increased | 0 | 1.5 |
| Blood creatine phosphokinase increased | 0 | 1.5 |
| Liver function test abnormal | 1.4 | 1.5 |
| White blood cell count decreased | 1.4 | 0 |
| percentage of Participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Numbness (at baseline) | 2.9 | 7.4 |
| Numbness (at 24 week) | 7.2 | 9.4 |
| Staggering (at baseline) | 1.4 | 8.8 |
| Staggering (at 24 week) | 2.9 | 3.1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind MCI-186 | — | 11/69 (15.9%) | 57/69 (82.6%) |
| Double-blind Placebo of MCI-186 | — | 16/68 (23.5%) | 51/68 (75%) |
| Open-label MCI-186 (Double-blind MCI-186, Then Open-label) | — | 17/65 (26.2%) | 53/65 (81.5%) |
| Open-label MCI-186 (Double-blind Placebo, Then Open-label) | — | 23/58 (39.7%) | 48/58 (82.8%) |
| Event | Double-blind MCI-186 | Double-blind Placebo of MCI-186 | Open-label MCI-186 (Double-blind MCI-186, Then Open-label) | Open-label MCI-186 (Double-blind Placebo, Then Open-label) |
|---|---|---|---|---|
| DysphagiaGastrointestinal disorders | 8/69 | 8/68 | 6/65 | 13/58 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 2/69 | 2/68 | 4/65 | 4/58 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/69 | 2/68 | 2/65 | 3/58 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/69 | 0/68 | 1/65 | 3/58 |
| Musculoskeletal disorderMusculoskeletal and connective tissue disorders | 0/69 | 1/68 | 3/65 | 2/58 |
| Speech disorderNervous system disorders | 1/69 | 2/68 | 2/65 | 1/58 |
| Gait disturbanceGeneral disorders | 0/69 | 0/68 | 2/65 | 0/58 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/69 | 1/68 | 0/65 | 1/58 |
| ContusionInjury, poisoning and procedural complications | 0/69 | 1/68 | 0/65 | 1/58 |
| DepressionPsychiatric disorders | 0/69 | 1/68 | 0/65 | 1/58 |
| Event | Double-blind MCI-186 | Double-blind Placebo of MCI-186 | Open-label MCI-186 (Double-blind MCI-186, Then Open-label) | Open-label MCI-186 (Double-blind Placebo, Then Open-label) |
|---|---|---|---|---|
| DysphagiaGastrointestinal disorders | 0/69 | 2/68 | 6/65 | 13/58 |
| ContusionInjury, poisoning and procedural complications | 13/69 | 8/68 | 6/65 | 6/58 |
| ConstipationGastrointestinal disorders | 8/69 | 8/68 | 7/65 | 8/58 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 8/69 | 3/68 | 3/65 | 1/58 |
| NasopharyngitisInfections and infestations | 3/69 | 5/68 | 6/65 | 4/58 |
| EczemaSkin and subcutaneous tissue disorders | 5/69 | 2/68 | 5/65 | 2/58 |
| PruritusSkin and subcutaneous tissue disorders | 0/69 | 3/68 | 5/65 | 1/58 |
| HeadacheNervous system disorders | 4/69 | 5/68 | 1/65 | 3/58 |
| InsomniaPsychiatric disorders | 5/69 | 4/68 | 2/65 | 2/58 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 5/69 | 2/68 | 4/65 | 1/58 |
| Age, Categorical(Participants) | MCI-186 | Placebo of MCI-186 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 46 | 46 | 92 |
| >=65 years | 23 | 22 | 45 |
| Sex: Female, Male(Participants) | MCI-186 | Placebo of MCI-186 | Total |
|---|---|---|---|
| Female | 31 | 27 | 58 |
| Male | 38 | 41 | 79 |
Ran from Dec 2011 to primary completion in Sep 2014, 32 months.
Results were first posted in Dec 2018, 4 years 3 months after primary completion.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone
Amyotrophic Lateral Sclerosis →